Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline.
about
Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosaPathophysiology, Clinical Importance, and Management of Neurogenic Lower Urinary Tract Dysfunction Caused by Suprasacral Spinal Cord InjuryCarbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysisUrinary tract infections: epidemiology, mechanisms of infection and treatment optionsSusceptibility of Escherichia coli from community-acquired urinary tract infection to fosfomycin, nitrofurantoin, and temocillin in Korea.Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coliBayesian models leveraging bioactivity and cytotoxicity information for drug discovery.ESBLs: A Clear and Present Danger?Recurrent nitrofurantoin-induced giant cell interstitial pneumonia: Case report and literature review.Tigecycline treatment of urinary tract infection and prostatitis: case report and literature review.Role of Old Antibiotics in the Era of Antibiotic Resistance. Highlighted Nitrofurantoin for the Treatment of Lower Urinary Tract InfectionsMultidrug Resistant CTX-M-Producing Escherichia coli: A Growing Threat among HIV Patients in India.Risk factors for extended-spectrum beta-lactamase-producing Escherichia coli infection in hospitalized patientsAdherence to Hospital Antibiotic Policy for Treatment of Escherichia coli ESBL in Urine.Bacteriology of Urine Specimens Obtained from Men with Symptomatic Benign Prostatic Hyperplasia.Clinical significance of extended-spectrum beta-lactamases.High rate of per oral mecillinam treatment failure in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli.Comparative Evaluation of Fosfomycin Activity with other Antimicrobial Agents against E.coli Isolates from Urinary Tract Infections.Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria.Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists.Management of Intra-abdominal Infections due to Carbapenemase-Producing Organisms.Tackling antimicrobial resistance in lower urinary tract infections: treatment options.Azoreductases in drug metabolism.Microarray Evaluation of Antimicrobial Resistance and Virulence of Escherichia coli Isolates from Portuguese Poultry.Prediction of infection caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: development of a clinical decision-making nomogram.Fosfomycin antimicrobial prophylaxis for transrectal ultrasound-guided biopsy of the prostate: A prospective randomised study.Comparison of community-onset healthcare-associated and hospital-acquired urinary infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and antimicrobial activities.Pharmacodynamic studies of nitrofurantoin against common uropathogens.The therapeutic effect of tigecycline, unlike that of Ceftazidime, is not influenced by whether the Klebsiella pneumoniae strain produces extended-spectrum β-lactamases in experimental pneumonia in rats.Fosfomycin activity versus carbapenem-resistant Enterobacteriaceae and vancomycin-resistant Enterococcus, Detroit, 2008-10.Increasing prevalence of ciprofloxacin resistance in extended-spectrum-β-lactamase-producing Escherichia coli urinary isolates.Membrane-Active Hydantoin Derivatives as Antibiotic Agents.Biofilm Formation in Nonmultidrug-resistant Escherichia coli Isolated from Patients with Urinary Tract Infection in Isfahan, Iran.An infectious disease and pharmacokinetic perspective on oral antibiotic treatment of uncomplicated urinary tract infections due to multidrug-resistant Gram-negative uropathogens: the importance of urinary antibiotic concentrations and urinary pH.Extended-spectrum β-lactamase-producing Enterobacteriaceae: in vitro susceptibility to fosfomycin, nitrofurantoin and tigecycline.
P2860
Q24612271-BBCABC52-4659-42C0-BAE5-4847244AEFF5Q26741369-3A40EF45-48E5-4EA1-B720-EFBD0E057705Q27002495-DE3C9618-2AE1-41CA-AB40-045E9A56440DQ27022487-4C8048B1-BD8F-440B-AB52-CBC82B9E7AE5Q34030071-0488E231-CA64-4144-A167-8315390998FBQ34108735-D7CFB25D-75E6-4C2E-ADF8-6609E16C4749Q34632430-00618169-8267-4A3E-9A9A-6A2CB009DE85Q35101453-1D50D790-84EE-465F-83C4-1C83EBE3326EQ35166745-6582D5AF-0C60-4438-B5D4-D4B3665454C1Q36048290-C1901F35-6189-4994-BAD1-4A0CB6384382Q36683599-EF80ED98-1BD8-47CB-A3DE-10005EFF921DQ36792780-32B36B34-F8CE-4391-9FE2-B0E4A7605F6DQ36797179-AD3D2D4A-2BF2-4B3F-9382-52AF2C842930Q36830992-B0409285-3FEC-48CA-A111-E96FE58799CDQ37237513-E0D990A3-3868-469A-8C38-84AEA6662EF1Q37291354-CEB740BE-E2FD-412D-8085-5B105CC8D7ADQ37484304-E23C06AF-1B75-423B-B5C6-341FE244E4C3Q37734217-F82FE32D-1EAD-4B7F-9DC0-082528D9276BQ38160759-148B8406-1FBE-4827-BE13-5092F24D1B3EQ38208281-3E5B78A0-2AAF-49E8-B12F-50E10FE57947Q38240411-81EA86A8-E882-4A4B-BFA5-3F2C8D7B0D35Q38833839-FAC8CFA1-F436-4301-B762-54EDB8559D38Q38917152-CB93B238-3DFB-4BFC-A2A4-E293387F7763Q39594220-6D17B714-C125-4811-A5C1-E25D09BCD749Q40053362-A871A1E3-84F5-428E-A129-6282DE47837BQ40567945-3693E28A-6FFD-4FB9-A683-B8C52BA42C65Q41433212-910B96C5-C3E6-425A-B421-AA6B93C7CD8FQ41595585-28E7EB6E-5203-47DE-A597-8DE679D7C78CQ41787127-4C3B2553-3859-4A4A-918F-53284CCE1130Q42261308-6DCDE86F-27FE-4F8A-8122-0568D98506BBQ42277205-80332FE4-01FC-4ED1-8685-F838B29ACD17Q47595624-6342EE90-F58D-4813-8D78-021AED379B70Q53695271-D1CDCC03-CBED-41A1-888A-3EC69483BAACQ53798070-ECF86F99-3E79-454C-BA97-9CB0C6FC492AQ54333977-B32DFDBB-79B6-4803-B204-39DBBD0927EE
P2860
Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Other antimicrobials of intere ...... itrofurantoin and tigecycline.
@ast
Other antimicrobials of intere ...... itrofurantoin and tigecycline.
@en
Other antimicrobials of intere ...... itrofurantoin and tigecycline.
@nl
type
label
Other antimicrobials of intere ...... itrofurantoin and tigecycline.
@ast
Other antimicrobials of intere ...... itrofurantoin and tigecycline.
@en
Other antimicrobials of intere ...... itrofurantoin and tigecycline.
@nl
prefLabel
Other antimicrobials of intere ...... itrofurantoin and tigecycline.
@ast
Other antimicrobials of intere ...... itrofurantoin and tigecycline.
@en
Other antimicrobials of intere ...... itrofurantoin and tigecycline.
@nl
P1476
Other antimicrobials of intere ...... itrofurantoin and tigecycline.
@en
P2093
P304
P356
10.1111/J.1469-0691.2007.01852.X
P478
14 Suppl 1
P577
2008-01-01T00:00:00Z